
Federal authorities have charged John Thomas Howard, treasurer and director of CANARX, with smuggling, conspiracy, introducing misbranded drugs into interstate commerce, and illegal drug importation. His brother, Bob Howard, who serves as president and director of the company, is also under investigation and subject to an arrest warrant but has not yet been taken into custody, according to court records filed Tuesday.
CARARX, based in Windsor, Ontario, Canada, is part of a growing sector of alternative funding programs that import prescription medications from countries such as Canada, the United Kingdom, Australia, and New Zealand to offer U.S. patients more affordable access to high-cost specialty drugs. These companies have partnered with private and public employers, and in some cases employers mandate their staff use such programs. However, federal authorities have characterized the practice of obtaining medications overseas and shipping them directly to patients as illegal and potentially unsafe, as it involves an unauthorized supply chain that pharmaceutical manufacturers have not approved.
The company has faced regulatory scrutiny for several years. The FDA issued a warning letter in 2019 alleging the company was substituting unapproved drugs for FDA-approved medications prescribed by U.S. healthcare providers. In 2023, the agency seized medications being shipped by CANARX that it determined were potentially misbranded and counterfeit. The criminal complaint covers activities from February 2017 through April 2026, though the affidavit does not specify which particular medications were allegedly imported illegally.
Company general counsel Joseph Morris stated that the Howards deny all charges and expect to be vindicated in court. The company has maintained that it operates legally and that medicines shipped to patients originate from highly regulated countries. The central legal question involves whether importing prescription drugs into the United States for personal use constitutes illegal smuggling or falls within FDA allowances for individual importation when medications are unavailable domestically.
Separately, pharmaceutical company Gilead Sciences has filed a civil lawsuit against CANARX and other firms, alleging illegal importation of Biktarvy, an HIV treatment medication. Gilead stated it has taken legal action to protect patients and the integrity of the U.S. medicines supply chain.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI